Accessibility Menu
GH Research logo

GH Research

(NASDAQ) GHRS

Current Price$28.70
Market Cap$1.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+49%
5 Year+64%
1 Year+66%
1 Month+32%
GH Research last closing stock price
MetricPriceDate
Last closeUSD 28.712026-07-17
GH Research stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.3%USD 26.512026-07-10
1 month+32.3%USD 21.702026-06-17
3 month+56.54%USD 18.342026-04-17
Year to date+126.06%USD 12.702025-12-31
1 year+66.43%USD 17.252025-07-17
3 year+119.16%USD 13.102023-07-18
5 year+64.06%USD 17.502021-07-16
Since inception+49.14%USD 19.252021-06-25

GH Research Financials at a Glance

Market Cap

$1.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$56.41M

EPS (TTM)

-$0.91

P/E Ratio

-31.57

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Price

$28.70

Volume

637,506.549

Open

$28.75

Previous Close

$28.71

Daily Range

$27.50 - $30.59

52-Week Range

$11.32 - $31.00

Estimated Earnings Date

Aug 6, 2026

GHRS News

Hands holding some pills from a bottle

5 Best Psychedelic Stocks for 2026 and How to Invest

Keith SpeightsJul 10, 2026

GHRS: Motley Fool Moneyball Superscore

54

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GH Research

GH Research PLC is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for psychiatric and neurological conditions. The company specializes in 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, particularly for patients with treatment-resistant depression (TRD).

Products and Services
  • GH001: Inhalable 5-MeO-DMT product candidate for TRD
  • GH002: Injectable 5-MeO-DMT candidate in preclinical development
  • GH003: Intranasal 5-MeO-DMT candidate targeting various psychiatric disorders
Growth Outlook
  • Strong focus on TRD, a growing market with significant unmet needs
  • Successful completion of multiple Phase 1 clinical trials for GH001
  • Expansion into additional psychiatric and neurological disorders with GH002 and GH003
Financial Highlights
  • Cash and short-term investments of $267.3 million as of March 31, 2026
  • Operating expenses of $18.7 million reported in Q1 2026
  • Net income of -$18.97 million for Q1 2026, reflecting ongoing R&D investments
GH Research PLC is positioned in a promising sector, focusing on innovative treatments for mental health conditions. The company's lead product, GH001, has shown potential in clinical trials, indicating a strong foundation for future growth. With substantial cash reserves, GH Research is well-equipped to continue its research and development efforts. The ongoing development of GH002 and GH003 further diversifies the company's pipeline, potentially addressing a broader range of psychiatric disorders. Investors may find GH Research's commitment to addressing significant mental health challenges appealing, especially as the demand for effective treatments continues to rise.
AI Generated • Jun 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

73

CEO

Villy Valcheva, MD

Website

www.ghres.com

Headquarters

Dublin, DU D02 NX43, IE

GHRS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-19.83%

Return on Capital

-21.65%

Return on Assets

-20.49%

Earnings Yield

-3.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

68.56M

Volume

637.51K

Avg. Volume

292.75K

Financials (TTM)

Gross Profit

-$268.00K

Operating Income

-$66.69M

EBITDA

-$55.86M

Operating Cash Flow

-$46.33M

Capital Expenditure

-$181.36K

Free Cash Flow

-$46.51M

Cash & ST Invst.

$267.33M

Total Debt

$432.00K

GH Research Performance Analysis

GH Research annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
GH Research sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
GH Research annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.43144.0%
20232023-12-31USD -0.6858.5%
20242024-12-31USD -0.759.5%
20252025-12-31USD -0.795.6%
GH Research sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3021.1%
Q32025-09-30-53.3%
Q42025-12-31N/A
Q12026-03-31-34.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$91.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$26.96M

N/A

Employees

73

N/A

Net Income

-$18.97M

-75.4%

EBITDA

-$18.79M

-75.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$267.33M

-8.2%

Total Debt

$432.00K

-34.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$75.00K

-76.7%

Short Term Debt

$357.00K

+6.3%

Return on Assets

-20.49%

N/A

Return on Invested Capital

-25.31%

N/A

Free Cash Flow

-$10.73M

-25.1%

Operating Cash Flow

-$10.67M

-24.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NBTXNanobiotix S.A.
$37.79+0.69%
TYRATyra Biosciences, Inc.
$32.13+1.65%
PVLAPalvella Therapeutics, Inc.
$157.24+6.41%
SVRASavara Inc.
$5.52+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
INTCIntel
$95.04-0.02%
NOKNokia
$10.12-0.03%
PATHUiPath
$12.15+0.01%

Questions About GHRS

What is the current price of GH Research?

GH Research is trading at $28.71 per share.

What is the 52-week range for GH Research?

Over the past 52 weeks, GH Research has traded between $11.32 and $31.00.

How much debt does GH Research have?

As of the most recent reporting period, GH Research reported total debt of $432.00K.

How much cash does GH Research have on hand?

GH Research reported $242.65M in cash and cash equivalents in its most recent financial results.

What is GH Research’s dividend yield?

GH Research does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services